Documentation

Press release

Datesort descending Press release
30/05/2017 - 7:30 CET Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board
31/05/2017 - 18:20 CET Résultat des votes de l’Assemblée Générale du 29 mai 2017 (Only in french)
06/06/2017 - 18:00 CET Inventiva to Present at the Jefferies 2017 Global Healthcare Conference
20/06/2017 - 18:00 CET Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models
29/06/2017 - 18:00 CET Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference
05/07/2017 - 18:00 CET Inventiva Announces First-half 2017 Financial and Corporate Update
27/07/2017 - 17:45 CET Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA
10/08/2017 - 17:45 CET Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA
29/08/2017 - 7:30 CET Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency
04/09/2017 - 7:30 CET Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule RORγ Inverse Agonist Drug Candidates
05/09/2017 - 7:30 CET Inventiva announces exercise of option by Boehringer Ingelheim to jointly develop potential new treatments for idiopathic pulmonary fibrosis (IPF)
18/09/2017 - 17:45 CET Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)
26/09/2017 - 18:30 CET INVENTIVA: FIRST-HALF 2017 RESULTS
17/10/2017 - 18:00 CET Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment
07/11/2017 - 18:00 CET Inventiva: third-quarter 2017 financial information
13/11/2017 - 17:45 CET Inventiva to Present at Two Upcoming Investor Conferences
03/01/2018 - 17:45 CET Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
04/01/2018 - 17:45 CET Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor

Pages